Terlipressin is an analogue of vasopressin that has potent vasoactive properties and has been available for use in most countries for nearly two decades. It has both established roles and emerging indications in the management of complications of decompensated chronic liver disease. We explore historic and emerging literature regarding the use of terlipressin for a range of indications including hepatorenal syndrome, portal hypertensive bleeding, and disruptions in sodium homeostasis. Novel methods of infusion-based terlipressin administration including the beneficial effect in reduction of adverse events are explored, in addition to new indications for the use of terlipressin in decompensated cirrhosis in an outpatient setting.
Terlipressin is an analogue of vasopressin that has potent vasoactive properties and has been available for use in most countries worldwide for nearly two decades. Terlipressin acts through the V1a receptors, which are located predominately on vascular smooth muscle within the splanchnic circulation, resulting in splanchnic vasoconstriction. 1 The terlipressin-induced splanchnic vasoconstriction gives rise to increased renal blood flow and has beneficial effects on hepatorenal syndrome (HRS) while at the same time reducing portal pressure and playing a role in reducing the risk of portal hypertensive bleeding.
These unique effects of the drug have translated into terlipressin playing a crucial role in the management of HRS and variceal bleeding for many years. Over more recent times, there has been an expansion of the indications for terlipressin usage and a broadening in the methods available for drug delivery. Its established roles and emerging indications will be examined in this review.
Terlipressin for hepatorenal syndrome
For clinicians who regularly use terlipressin, there is little doubt in their minds regarding the efficacy of this drug for the treatment of HRS. However, issues with trial design in this area and strict registration criteria with the Food and Drug Administration mean that terlipressin is still not available for use within the USA. Table 1 shows the key studies examining the use of terlipressin for the management of HRS.
The original studies describing the efficacy of terlipressin in the treatment of HRS now date back more than 20 years, 2 with multiple publications subsequently demonstrating terlipressin to be effective in improving renal function in patients with HRS. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] One of the studies published in 2000 described a small case series involving nine patients. 4 All had HRS as defined by the diagnostic criteria stipulated by the International Club of Ascites (ICA) 15 including (i) low glomerular filtration rate, as indicated by serum creatinine (SCr) > 133 μmol/L; (ii) absence of shock, ongoing bacterial infection, fluid losses, and treatment with nephrotoxic drugs; (iii) no improvement of renal function following diuretic withdrawal and plasma volume expansion; (iv) proteinuria < 500 mg/day; and (v) no renal tract obstruction on imaging. Terlipressin was administered at a dose of 0.5-1 mg 4 hourly for 15 days or until SCr fell to < 133 μmol/L. A reversal of HRS was defined as a reduction in SCr to < 133 μmol/L and was achieved in seven of the nine patients. With the substantial limitation of the lack of a control arm, significant improvements from baseline included reduction in SCr and increase in serum sodium, 24-h urinary volume, and mean arterial pressure (MAP) (P < 0.05). Despite these promising results, the beneficial effects of terlipressin for HRS needed to be proven in larger randomized control trials (RCTs).
The first prospective RCT of terlipressin for HRS was published by the New Delhi Group in 2003. 3 This study's inclusion criteria stipulated an SCr of > 221 μmol/L or 50% reduction in creatinine clearance within a 2-week period, in addition to the ICA criteria for HRS. Group A (n = 12) were randomized to 1 mg terlipressin b.i.d., and Group B (n = 12) received placebo. Both groups also received renal dose dopamine for the first 24-48 h following enrolment. The terlipressin group achieved a significant decrease in SCr compared with placebo at day 8. No comparative data are available for day 15 SCr, as no patients in the placebo arm survived to this time point. There was a survival benefit at D15 in those treated with terlipressin (P < 0.05); however, participants were not followed beyond day 15 limiting conclusions regarding long-term survival or sustained HRS reversal.
A second larger RCT was thereafter conducted in Italy, including secondary outcomes to determine the benefit of terlipressin on intermediate and long-term survival. 8 Group A (n = 26) received 1 mg terlipressin t.d.s. for 5 days and then subsequently 0.5 mg t.d.s. for an additional 14 days in conjunction with intravenous (i.v.) albumin. Group B (n = 26) received i.v. albumin infusions alone. Both groups were followed for 3 months, and if initial response was achieved, retreatment with the same regimen was allowed if HRS recurred. Survival was greater at day 15, and 180 in those treated with terlipressin (P < 0.05) and patients in Group A were more likely to achieve reversal of HRS (SCr < 133 μmol/L) compared with group B (P < 0.05).
With the promising results of these two small RCTs, a larger multicenter RCT was performed in the USA in 2008. 6 This study established a more stringent primary end-point compared with other HRS RCTs being, "treatment success", defined as those participants at day 14 with resolution of HRS, with a documented SCr < 133 μmol/L, on two occasions, at least 48 h apart without intervening transplantation, dialysis, or death. In this third RCT, 112 patients with decompensated cirrhosis were randomized across 35 centers to either terlipressin or placebo. The terlipressin group was initially treated with 1 mg q.i.d., which was increased at day 3 to 2 mg q.i.d. if the SCr had not fallen by at least 30% from baseline. "Treatment success" was achieved by 14/56 (25%) patients in the terlipressin arm and 7/56 (12.5%) patients in the control arm; however, this difference did not reach statistical significance (P = 0.093). Regarding the end-point commonly used in the earlier RCTs of reduction of SCr to < 133 μmol/L on one occasion, the terlipressin group did achieve a superior result compared with the control arm (P < 0.05). There was no survival benefit at any time point to day 180 (P > 0.05).
In an attempt to get terlipressin approved for HRS in North America, a second large RCT was subsequently performed. 16 The terlipressin cohort (n = 97) received 1 mg q.i.d., which was increased to 2 mg q.i.d. at day 4 if SCr had not decreased by > 30% from baseline. The control group (n = 99) received albumin infusion alone. The primary end-point was "confirmed HRS reversal" defined as SCr < 133 μmol/L on two occasions, at least 40 h apart, within 24 h of the last dose of terlipressin. More patients treated with terlipressin compared with placebo achieved "confirmed HRS reversal" (19.6% vs 13.1%); however, this did not reach statistical significance (P = 0.22). There was, however, a significant reduction in mean SCr from baseline to end of treatment in the terlipressin group compared with placebo (P < 0.001).
Although this study failed to achieve the primary end-point, potential issues within the study were identified. Of note, three patients within the terlipressin group who achieved reversal of HRS (creatinine < 133 μmol/L on one occasion) were discharged from hospital before a second creatinine could be collected and thus were not included as achieving "confirmed HRS reversal." The failure of this most recent large RCT to show a clear benefit of terlipressin for the management of HRS type 1 has resulted in the lack of availability of this medication in the USA. Further Current and emerging indications T Papaluca and P Gow studies of the use of terlipressin for HRS are currently underway in North America to hopefully provide the data necessary for Food and Drug Administration registration. The large variation in response rates to terlipressin therapy may be related to the difference in mean SCr at baseline in these studies. The greater response rates in regard to reversal of HRS in patients treated with terlipressin in combination to albumin, relative to those in who received albumin therapy along, were seen in studies with a lower mean baseline SCr of 256, 248, and 255 μmol/L compared with an alternate study in excess of 340 μmol/L. 3, 6, 8, 17 SCr is relatively reliable of representing actual renal function in patients with compensated cirrhosis; however, it performs far less adequately in decompensated cirrhosis owing to comorbid sarcopenia and the significant reduction in creatine to creatinine conversion within the liver and reduction in release from muscle mass. 18 Herein, some decompensated cirrhotic patients may in fact have normal SCr despite significant acute renal failure. 19 As such, patients with significant, albeit milder, acute renal failure may not be appropriately diagnosed and managed until the nominal figure of 133 μmol/L is reached to fulfill the ICA diagnostic criteria, exposing them to much severer acute renal failure before therapy is initiated. As such, a working party addressing renal dysfunction in cirrhosis have proposed new criteria for the diagnosis of acute kidney injury in cirrhosis in a bid to reduce morbidity and mortality and to improve treatment response. 20 The group have proposed that a diagnosis of acute renal impairment and initial management thereof should be instituted in those patients experiencing an SCr increase > 50% from baseline or > 26.4 μmol/L in a 48-h period without necessarily reaching an SCr of 133 μmol/L. These criteria allow for earlier intervention in patients with a lesser degree of renal failure, likely improving the chances of a successful outcome.
Multiple studies have described a significant benefit of reduced mortality in patients for HRS in patients who responded to terlipressin therapy compared with placebo. 3, 8, 17 Neri et al. demonstrated that the probability of survival was significantly higher in the subjects treated with terlipressin who had a response to therapy (P < 0.0001), with one of only two predictors of survival on multivariate analysis being SCr reduction on therapy (P < 0.001). 8 An alternate non-controlled study found response to terlipressin to be positively associated with 3-month survival compared with non-responders (P = 0.03) with a significantly higher HRS reversal rate compared with a group of matched historical controls. 17 An improvement in SCr not only demonstrates terlipressin response but further an increasing percentage improvement of SCr on treatment is highly correlated with improved survival. 21 The North American studies however failed to demonstrate a mortality benefit in patients treated with terlipressin compared with albumin therapy alone, owing to a lack of a significant HRS reversal response rates between the two cohorts. However, the cumulative responders (irrespective of treatment) had improved survival compared with non-responders in both studies, 6, 16 which is unsurprising given reversal of HRS is associated with reduced mortality. Reduction in mortality in patients treated with terlipressin for HRS was recently addressed in a Cochrane review published in 2017 with data included from nine large high-quality RCTs and an analysis of 534 participants 22 -this demonstrated a reduction in mortality in patients with HRS treated with terlipressin compared with placebo/no intervention with a risk ration of 0.85 (95% confidence interval 0.73 to 0.98) and a number needed to treat for an additional beneficial outcome to prevent one death of 10.
Predictors of response to terlipressin for the management of hepatorenal syndrome
The aforementioned data studies demonstrate that there is a wide range of response to terlipressin therapy. Multiple studies have tried to elicit predictors of response to terlipressin therapy. One such study 23 demonstrated on univariate and multivariate analysis that a lower baseline serum bilirubin was associated with response to terlipressin therapy-HRS reversal in patients treated with terlipressin was seen in 67% of participants with an initial serum bilirubin of < 171 μmol/L compared with only 13% in those participants with bilirubin > 171 μmol/L (P < 0.01). 23 An increase in MAP at day 3 of > 5 mmHg was also associated with an increased likelihood of HRS reversal when treated with terlipressin-73% of patients with > 5 mmHg increase in MAP achieved HRS reversal versus 36% in patients with < 5 mmHg increase (P < 0.05). 23 A lower baseline creatinine was associated response to terlipressin therapy [247.5 vs 291.7 μmol/L] (P < 0.05) in addition to a range of markers of less severe hepatic impairment including a lower international normalized ratio, model for endstage liver disease (MELD), and Child-Pugh scores (P < 0.05). 17 A large analysis regarding predictors of response to terlipressin therapy for HRS suggests that the greatest benefit of terlipressin over albumin therapy alone was in patients with an initial SCr between 265 and 442 μmol/L, where the absolute difference in reversal of HRS was 22% favoring terlipressin. 24 The highest initial SCr in this group in which HRS reversal was achieved was 495 μmol/L, and the group suggested that treatment is likely futile with an initial SCr > 618 μmol/L. The authors do however reference a case in which a patient with HRS treated with terlipressin with an initial SCr of 734 μmol/L achieved HRS reversal. 4 A further study supported a lower baseline creatinine being associated with increased response to terlipressin therapy. 13 
Terlipressin compared with ocreotide/midodrine for hepatorenal syndrome
Terlipressin has been demonstrated to be superior to alternate therapies for HRS commonly used in North America. Cavallin et al. 9 conducted a prospective RCT comparing terlipressin therapy to combination midodrine and ocreotide, with both arms receiving daily albumin infusion. Forty-nine patients with HRS in keeping with the ICA diagnostic criteria were randomized to receive either terlipressin or ocreotide/midodrine. The terlipressin group (n = 27) were commenced on 3 mg daily, infused over 24 h, which could be incremented to a maximal dose of 12 mg/day. The ocreotide/midodrine (n = 22) were administered 100 mcg/7.5 mg t.d.s., respectively, which could be increased to a maximal dose of 200 mcg/12.5 mg t.d.s. These therapies were continued for an additional 24 h beyond reversal of HRS (defined as creatinine < 133 mmol/L) or a total duration of 14 days. The primary end-point was defined as reversal of HRS, which was achieved in 55.8% of the terlipressin group compared with only 4.8% of the ocreotide/midodrine cohort (P < 0.001).
Terlipressin versus noradrenaline for hepatorenal syndrome:
Noradrenaline (NA) is a catecholamine with predominantly alphaadrenergic activity, which has been shown to have a renal vasodilatory effect and improve renal blood flow. 25, 26 As such, it was postulated that it would have similar efficacy to terlipressin for the treatment of HRS. Following an initial small pilot trial, five prospective, randomized, open-labeled studies have compared the efficacy of terlipressin with NA for the management of HRS. All have shown similar efficacy between the two therapies. [27] [28] [29] [30] [31] [32] Sharma et al. 27 performed an open-label, randomized, controlled trial of NA compared with terlipressin for the treatment of type 1 HRS. Forty consecutive patients were recruited with HRS and creatinine > 221 μmol/L. All patients underwent volume expansion with albumin 60 g/day for 2 consecutive days, and if urine output (UO) remained < 600 mL/day or SCr > 133 μmol/L, they were randomized to treatment with terlipressin or NA. Group A (n = 20) were commenced on NA 0.5 mg/h with target to increase systolic blood pressure by 10 mmHg and UO to > 50 mL/h. If this was not achieved at 4 h, NA was increased by 0.5 mg/h to a maximum of 3 mg/h. Group B (n = 20) were commenced on terlipressin 0.5 mg q.i.d. and were dose escalated by 0.5 mg q.i.d. if SCr had not fallen by > 88 μmol/L over a 3-day period. The groups were followed for 15 days. Both groups demonstrated a statistically significant improvement in SCr, serum sodium, creatinine clearance, mean UO, and mean MAP (P < 0.05). Moreover, there was no significant intergroup difference in these parameters nor was there any difference in survival at 15 days between the terlipressin and NA arms (group A 55% vs group B 55%, P = 0.798).
The comparative effect of NA on HRS was also demonstrated in a further open label RCT in India. Singh et al. 28 randomized 46 patients into two groups to receive either terlipressin (n = 23) or NA (n = 23) in addition to 20 g/day of albumin. The same dosing regimen and monitoring approach was utilized as per the previous study. 9 Irrespective of treatment arm, both groups achieved a significant reduction in SCr and an increase in UO and MAP without significant differences in benefit between the groups (P > 0.05). Moreover, in concordance with the earlier RCT, there was no difference in response to therapy (defined as creatinine < 133 μmol/L) between the terlipressin and NA groups (39.1% vs 43.3%, respectively, P > 0.05) nor differences in survival at 15 days (39.1% vs 47.8%, P = 0.46). This study also demonstrated a significant cost reduction in regard to pharmaceuticals alone in the NA group compared with terlipressin (€275 vs €975, P < 0.05).
The five RCTs comparing NA and terlipressin for the management of HRS [27] [28] [29] [30] [31] reveal that both therapies have similar efficacy, and as such, NA remains a suitable alternative to terlipressin when this therapy is unavailable or where patients need pressor support for circulatory failure. In patients who do not require intensive care, terlipressin has a clear advantage in that it can be safely administered in a hospital general ward without the requirement for intensive and invasive monitoring.
Terlipressin for the management of variceal bleeding
Terlipressin versus ocreotide in the management of variceal bleeding. Terlipressin has been demonstrated to have greater efficacy in reducing esophageal variceal pressure compared with ocreotide. 33 In one study, 27 patients were administered either a bolus of 2 mg terlipressin, 50 mcg ocreotide, or distilled water i.v. in three treatment arms, and pressure measurements were collected using a speciality endoscopic probe applied directly to the varix. There was a significant reduction in mean variceal pressure by 27% in the terlipressin group without significant change in the remaining groups (P < 0.05).
An alternate study assessed the hemodynamic effects including MAP, heart rate, hepatic venous pressure gradient (HVPG), and portal venous flow assessed by duplex doppler ultrasonography at baseline and then 1, 5, 10, 20, and 25 min after administration of i.v. boluses of terlipressin, ocreotide infusion, or placebo. 34 An infusion of 250 mcg of ocreotide was associated with a rapid significant reduction in HVPG and PVG at 1 min (P < 0.05); however, pressures measurements had returned to baseline valves at all other subsequent time points. Conversely, Terlipressin administration was associated with a significant decrease in HVPG and portal venous flow, which was sustained at all time points (P < 0.05).
Multiple smaller prospective, placebo-controlled RCTs have demonstrated terlipressin to be superior to placebo regarding likelihood of active variceal bleeding at index gastroscopy, reduced re-bleeding rates, and reduced transfusion requirement [35] [36] [37] ; however, these studies predated modern band ligation techniques now used as standard of care in variceal hemorrhage.
With this early data suggesting a greater effect of terlipressin over octreotide at reducing variceal pressure, several studies have attempted to demonstrate this benefit on clinically significant endpoints. [38] [39] [40] [41] [42] A recent, large RCT assessed the outcomes of patients presenting with variceal bleeding with adjuvant treatment with either terlipressin, somastostatin, or ocreotide. 43 Seven hundred and eighty patients presenting with variceal hemorrhage were enrolled across 11 Korean centers and were commenced on either Terlipressin [2 mg bolus then 1 mg q.i.d. for 5 days] (n = 261), somatostatin [250 mcg bolus then 250 mch/h for 5 days] (n = 259) or octreotide [50 mcg bolus then 25 mcg/h]. At the time of the index gastroscopy, there was no significant difference in active bleeding rates between the three treatment arms (46.0%, 46.2%, and 46.5%) nor between rates of bleeding control without rescue therapy (balloon tamponade, transjugular intrahepatic portosystematic stent shunt [TIPSS]) (89.7%, 87.6%, and 88.1%, P = 0.752). In addition, there was no significant difference in rates of re-bleeding within the 5-day treatment period between the three therapies nor in mortality rates.
A second double-blind RCT explored whether there were differences in clinical outcomes between terlipressin and ocreotide therapy in patients presenting with variceal bleeding. 44 In this study, 324 patients were randomized to either terlipressin or octreotide in addition to standard endoscopic therapy. The only significant difference demonstrated was that patients treated with terlipressin were less likely to have active bleeding at the time of index gastroscopy (16% vs 25.5%, respectively, P = 0.034). However, there were no significant differences in other clinical outcomes including mortality.
Despite improved portal hemodynamics with terlipressin compared to ocreotide, the only significant benefit of terlipressin identified in these trials was active bleeding at time of index gastroscopy while re-bleeding, and mortality rates are unchanged. The standard of care for acute variceal bleeding remains pharmacological therapy (with either octreotide or terlipressin) in combination with endoscopic variceal band ligation. There remains little doubt that terlipressin exerts a greater physiological effect on variceal pressure compared with octreotide. The explanation as to why this does not translate into any clinically significant benefit over octreotide in patients presenting with variceal bleeding likely lies with the fact that most of the efficacy of therapy resides with endoscopic variceal band ligation with a relatively small additional component from the pharmacological therapy.
Terlipressin's effect on serum sodium concentration
While terlipressin is largely used for its activation of the V1a receptor, it is also recognized that terlipressin also causes activation of the V2 renal receptors. 45 Stimulation of the V2 receptor leads to an increase in aquaporin 2 in the renal collecting duct and thus increased solute free water absorption and can potentially result in hyponatremia. 45 There have been multiple publications that have explored the effect of terlipressin on serum sodium concentrations [45] [46] [47] [48] [49] including several that describe neurological complications from profound hyponatremia. [50] [51] [52] Most publications describe hyponatremia as a complication of terlipressin usage, while a retrospective Australian study reported the beneficial effect of terlipressin usage in conjunction with albumin infusion for the treatment of clinically significant hyponatremia.
One large retrospective study described the effect of terlipressin on serum sodium in 58 patients with portal hypertension and gastroesophageal variceal bleeding. 47 All were treated with terlipressin 2 mg 4 hourly initially and then subsequently reduced to a dose of 1 mg 4 hourly after 24 h for a total of 5 days. Across this population of patients, mean sodium fell from 134.9 ± 6.6 mmol/L at day 1 to 130.5 ± 7.7 mmol/L at day 5 of treatment (P = 0.002). There was significant variation in the magnitude of the fall in sodium. In 19 patients, it was < 5 mmol/L, 18 patients: 5-10 mmol/L (n = 18, 31%), and in 21 patients, serum sodium fell by > 10 mmol. Three of the 21 patients (14%) who experienced a decrease in sodium > 10 mmol/L had neurological sequelae including altered conscious state, coma, and, in one instance, seizures complicating osmotic demyelination in the setting of rapid correction of serum sodium. In 95% of cases, hyponatremia was resolved with withdrawal of terlipressin. Importantly, this population was compared with 174 contemporary patients treated with somatostatin for variceal bleeding where no change in serum sodium was observed during 5 days of therapy.
These findings are supported by a recent large retrospective study that documented the risk of hyponatremia when terlipressin is utilized for gastrointestinal bleeding. 53 Of the 151 patients in the series treated with terlipressin, 66.9% had a reduction in serum sodium of > 5 mmol/L, and 38.5% had reduction of > 10 mmol/L. In most cases, cessation of terlipressin resulted in rapid correction of serum sodium. Baseline serum sodium was also identified as a significant determinant in an alternate prospective study. 49 These publications contrast with an Australian study that described terlipressin as an effective therapy for profound hyponatremia in cirrhotic patients. 46 This group's retrospective case series described 23 cirrhotic patients who were commenced on terlipressin for the indication of hyponatremia unresponsive to fluid restriction and diuretic cessation. These patients were compared with 11 decompensated cirrhotic with hyponatremia managed with fluid restriction and albumin infusion alone. The dosage of terlipressin was between 0.5-1 mg 4 hourly for all patients, and they received albumin infusion 40 g daily. At 7 days, there was a significant increase in sodium from 120 to 129 mmol/L (P < 0.05) compared with no change in the albumin infusion only group at 123 mmol/L at baseline and remaining unchanged at day 7 (P > 0.05). Forty-eight percent (11/23) of the patients in the terlipressin group were able to recommence diuretics on terlipressin for the management of problematic fluid overload. The group postulated that the combination of albumin infusion in addition to terlipressin helped to augment the renal response to terlipressin increasing serum sodium. On multivariate and univariate analysis, the utilization of terlipressin was the only factor leading to resolution of hyponatremia.
The contrasting conclusions of these papers that explore the effect of terlipressin use on serum sodium need analysis. It is likely that the explanation for the disparate results relies on whether albumin was used in conjunction with terlipressin or not. The papers that described terlipressin causing hyponatremia did not use albumin as part of the routine therapy, whereas the Australian paper describing terlipressin as an effective therapy for hyponatremia did. Albumin infusion results in an increase in effective blood volume. This in turn leads on to decreased baroreceptor activation and reduced arginine vasopressin release and water retention. Thus, albumin-induced reduction in arginine vasopressin production overrides the terlipressin-induced V2 receptor stimulation with the net effect being positive free water clearance. Prescribing clinicians need to be mindful of terlipressin induced hyponatremia. Profound and life-threatening hyponatremia can result from this medication's use, and as such, patients need to be carefully monitored. When clinically significant hyponatremia results, albumin therapy should be instituted or terlipressin therapy should be withheld.
Continuous versus bolus terlipressin for hepatorenal syndrome
The current standard practice for terlipressin administration is that it is given by bolus doses every 4-6 h when used for either portal hypertensive bleeding or HRS. 54 However, the hemodynamic effect of terlipressin on portal pressure has been shown to last no more than 3-4 h. 55 This raises the question as to whether terlipressin administered by continuous infusion may have greater efficacy than standard bolus dose administration. Recently, important clinical data have been published comparing the two methods of administration.
The hemodynamic effects of either bolus or terlipressin infusion has been examined in a small cohort of patients undergoing TIPSS for the management of variceal bleeding or Budd-Chiari syndrome. 56 In total, 21 patients had TIPSS performed with a pressure catheter placed within the portal vein post-TIPSS insertion. Ten patients received a 1 mg terlipressin bolus followed by 4 mg infusion over 24 h, while the conventional intermittent bolus group received a 2 mg bolus initially and then 1 mg 4 hourly. In the group who received bolus dose terlipressin, a portal venous pressure fall > 20% from baseline was observed for only 4 h out of the total 24 h of the study period. This contrasted sharply with the continuous infusion group. In the latter group, portal pressure reduction > 20% from baseline was maintained throughout the 24-h monitoring period. Assessing area under the curve, there was a statistically significant reduction in portal pressures in the infusion group compared with the bolus group over the 24-h study period (P < 0.05).
It was postulated from a small retrospective study that when applied clinically, this would lead to a reduction in 24-h dosage requirement and reduced adverse effects. 57 An important prospective RCT was recently published exploring improved safety and efficacy when terlipressin was given by infusion versus bolus dose terlipressin in patients with HRS. 58 In this study, 78 patients with HRS were randomly assigned to a continuous infusion of terlipressin at 2 mg/day or bolus doses starting at 0.5 mg 4 hourly, and dose escalated if there was an inadequate response. Response to treatment was assessed in both groups at 48-h intervals, and if SCr had decremented < 25%, the amount of terlipressin was gradually increased to a maximum of 12 mg/day in both groups. Both groups received standard doses of albumin. Terlipressin was continued until resolution of HRS type 1 (creatinine < 133 μmol/L), liver transplantation, death, or to a maximal duration of 15 days. The primary end-point was the prevalence of drug-related adverse events, while secondary end-point included response to treatment (complete response defined as creatinine < 133 μmol/L and partial response a > 50% reduction in SCr) and 90-day transplant-free survival. Thirty-four patients were randomized to infusion administered terlipressin and 37 to bolus administration. The study revealed significantly fewer adverse events in the infusion group compared with those receiving the drug by bolus administration. Overall total adverse events were seen in 35% of those receiving the drug via infusion compared with 62% via bolus administration (P < 0.025). Severe adverse events were also less frequent in the infusion group (21% vs 43%, P < 0.05). Interestingly, the six patients in the terlipressin bolus group who experienced severe adverse events were commenced on salvage infusion-based terlipressin at an initial dose of 2 mg over 24 h. All six patients tolerated infusion-administered terlipressin, and all experienced complete response with SCr < 133 mmol/L (three patients at a dose of 2 mg/24 h and three at 4 mg/24 h). There was no statistically significant difference in the number of patients experiencing complete response to treatment between the two groups (infusion group 64.85% vs bolus group 76.47%, P > 0.05). There was no significant difference in the mean reduction of creatinine nor the mean time to achieve treatment response; however, the maximal and mean dose of terlipressin required to achieve response was lower in the infusion versus bolus administered group (2.23 ± 0.65 mg vs 3.51 ± 1.77 mg, P = 0.0001). There was no difference in transplant-free survival between the cohorts.
These important but preliminary studies suggest that there may be significant clinical differences in the safety and perhaps efficacy depending on the method of terlipressin administration. Further studies are needed to confirm these findings in patients with HRS and also in patients with variceal bleeding.
The use of ambulatory terlipressin infusion
There is a population of patients who are awaiting liver transplantation who have terlipressin-responsive HRS. For many patients in this group, attempts to wean terlipressin are met with recurrence of HRS. For this cohort of patients, the options are thus to remain on terlipressin until transplanted or to develop renal failure and commence renal replacement therapy. In this group of terlipressin-"dependent" patients, many may need the drug for months until a suitable organ becomes available for transplantation. This long term course of therapy has led to the initiation of programs that aim to deliver continuous terlipressin infusions in an ambulatory outpatient setting.
A case report from our own unit describes a 59-year-old gentleman with Child-Pugh C cirrhosis complicated by encephalopathy, diuretic refractory ascites, and hepatocellular carcinoma who was successfully bridged to transplantation with hospital-in-thehome-based terlipressin infusion for the management of HRS type 1. 59 The patient had two acute admissions in the preceding months with SCr > 400 μmol/L, which had been responsive to bolus dose terlipressin. He was commenced on terlipressin 3.0 mg/day via 24-h infusion with complete normalization of his renal function. Hospital-in-the-home nurses attended to the patient on a daily basis to ensure clinical stability and replace the 24-h infusion. No terlipressin-related adverse events were encountered during his 22 days of ambulatory therapy, and his HRS remained terlipressin responsive.
In a subsequent series, we have described six patients with HRS as defined by ICA who were successfully managed with ambulatory terlipressin infusions. 60 In all cases, patients received intermittent bolus administration of 0.85 mg as an inpatient for a mean of 6 days to confirm efficacy and tolerability before being transitioned to a 3.4 mg/24 h via a peripherally inserted central catheter infusion line. Two patients later tolerated a dose reduction to 1.7 mg/24 h without recurrence of HRS. Three patients were bridged to orthotopic liver transplantation with a mean of 21 days (range 1-37); one patient achieved reversal of HRS and remained stable without terlipressin after successful hepatitis C eradication therapy. The two remaining patients had their infusions ceased: one patient due to ongoing bleeding at a peripherally inserted central catheter infusion site, while the other patient was deemed inappropriate for transplantation. There was significant cost savings associated with the transfer of the care from the hospital to the hospital-in-the-home service.
The experience at this transplant center suggests that in carefully selected patients, the use of ambulatory terlipressin infusion is a safe, efficacious, and well-tolerated therapy for the management of HRS type 1 as a bridge to transplant, allowing patients to be managed beyond the confines of an inpatient ward.
Diuretic refractory ascites. The use of outpatient terlipressin infusion for the management of diuretic refractory ascites has been investigated in one small single center pilot study. 61 Five patients were included in the study. All were Child-Pugh C with a mean MELD score of 18. All five patients were undergoing weekly or fortnightly paracentesis for diuretic refractory ascites prior to enrolment. The five patients were commenced on a terlipressin infusion 3.4 mg/24 h via a peripherally inserted central catheter and followed for 4 weeks. The patients served as their own controls with parameters from the 4 weeks prior to the terlipressin infusion compared with the 4 weeks on therapy. Compared with the observation period, there was a significant reduction in volume of ascites drained during the treatment period (22.9 vs 11.9 L, P < 0.05) with two patients requiring no further paracentesis while on terlipressin therapy. There was a reduction in the number of paracentesis required (3.2 vs 2.2, P < 0.05) over the treatment period as well as an increase in 24-h urinary sodium excretion (88.3 vs 153.4 mmol/day, P < 0.05).
Conclusion
The unique pharmacological effects of terlipressin on the cirrhotic circulation are to reduce portal pressure and increase renal blood flow. These effects have been exploited in studies exploring its role in the management of HRS and variceal bleeding. Over more recent years, as the physiological effects of terlipressin have become better understood, roles for the drug in the setting of refractory ascites and cirrhotic hyponatremia have been proposed. In addition to its potentially expanded indications, the use of terlipressin as a continuous infusion rather than bolus administration and use in the outpatient setting have seen a reinvigoration in research and publications for this therapy. With a drug that has been available for more than 20 years, one might expect that clinical interest in the therapy may be diminishing. However, the opposite appears to be the case with terlipressin. There are currently more than 50 ongoing clinical studies exploring further expansion of the role of this medication. For clinicians involved in the management of patients with advanced liver disease, terlipressin plays a central role in the management of complications and is likely to play an expanded role in years to come.
